Table 3. Univariable and Multivariable Models Estimating Prognostic Outcomes of Prophylactic Salpingo-Oophorectomy Regarding Contralateral Breast Cancer, Breast Cancer–Specific Mortality, and Overall Survival by Variant Type, Histology, and Surrogate Molecular Subtype.
| Model | Contralateral breast cancer, any event | Breast cancer–specific mortality | Overall survival | |||
|---|---|---|---|---|---|---|
| sHR (95% CI) | P valuea | sHR (95% CI) | P valuea | HR (95% CI) | P valuea | |
| Univariable modelb | ||||||
| Yes vs no | 1.04 (0.70-1.53) | .86 | 0.87 (0.47-1.62) | .67 | 0.40 (0.25-0.64) | <.001 |
| Multivariable model without interactionb | ||||||
| Yes vs no | 1.03 (0.69-1.52) | .90 | 0.96 (0.52-1.80) | .91 | 0.43 (0.27-0.67) | .001 |
| Prophylactic oophorectomy and variant typeb | ||||||
| Yes vs no, with BRCA1 | 1.12 (0.69-1.82) | .81 | 0.93 (0.41-2.13) | .98 | 0.35 (0.20-0.63) | .001 |
| Yes vs no, with BRCA2 | 0.86 (0.44-1.70) | 1.04 (0.43-2.47) | 0.60 (0.28-1.27) | |||
| Interaction of oophorectomy with variant type | NA | .53 | NA | .86 | NA | .27 |
| Prophylactic oophorectomy and histologyb | ||||||
| Yes vs no for ILC | 0.10 (0.01-0.78) | .10 | 0.70 (0.11-4.30) | .60 | 0.26 (0.05-1.23) | .008 |
| Yes vs no for IDC | 1.14 (0.74-1.77) | 0.90 (0.46-1.79) | 0.51 (0.31-0.84) | |||
| Yes vs no for medullary carcinoma | 2.63 (0.80-8.63) | 6.07 (0.37-99.12) | 0.21 (0.03-1.63) | |||
| Yes vs no, with other invasive histology | 1.19 (0.22-6.47) | Unable to estimate riskc | Unable to estimate riskc | |||
| Interaction of oophorectomy with histology | NA | .06 | NA | .40 | NA | .54 |
| Prophylactic oophorectomy and surrogate molecular subtypeb,d | ||||||
| Yes vs no for triple negative | 1.73 (1.01-2.99) | .09 | 0.70 (0.24-2.01) | .59 | 0.21 (0.09-0.46) | .002 |
| Yes vs no for luminal A | 0.94 (0.34-2.60) | 2.30 (0.40-13.36) | 1.34 (0.22-8.02) | |||
| Yes vs no for luminal B ERBB2 positive | Unable to estimate riskc | 3.88 (0.44-34.16) | 4.04 (0.37-44.62) | |||
| Yes vs no for luminal B ERBB2 negative | 0.34 (0.12-0.96) | 0.69 (0.21-2.23) | 0.48 (0.20-1.19) | |||
| Yes vs no for not available | 0.94 (0.35-2.56) | 1.90 (0.30-11.84) | 1.31 (0.40-4.31) | |||
| Interaction of oophorectomy with surrogate molecular subtype | NA | .050 | NA | .45 | NA | .02 |
Abbreviations: ERBB2 (formerly HER2 or HER2/neu), human epidermal growth factor receptor 2; HR, hazard ratio; IDC invasive ductal carcinoma; ILC, invasive lobular carcinoma; NA, not applicable; sHR, subdistribution hazard ratio.
a
From Wald test.
b
Tests of the null hypotheses that the prophylactic salpingo-oophorectomy coefficient, and coefficients for interactions between prophylactic salpingo-oophorectomy and variant status, histology, or surrogate molecular subtype, are 0.
c
Too few cases or events to estimate risks.
d
The ERBB2 subtype was omitted because it did not converge in any of the models due to low number of cases or events.